Abstract-The relative importance of various blood pressure indices on cardiovascular risk in people with type 2 diabetes mellitus has not been established. This study compares the strengths of the associations between different baseline blood pressure variables (systolic blood pressure [SBP], diastolic blood pressure [DBP], pulse pressure [PP], and mean arterial pressure) and the 4.3-year risk of major cardiovascular events in the Action in Diabetes and Vascular Disease: Preterax and Diamicron-Modified Release Controlled Evaluation Study. Mean (SD) age for the 11 140 participants was 65.8 years (6.4 years). During follow-up, 1000 major cardiovascular events, 559 major coronary events, and 468 cardiovascular deaths were recorded. After adjustment for age, sex, and treatment allocation, the hazard ratios (95% CIs) associated with 1 increment in SD for the risk of major cardiovascular events were 1.17 (1.10 to 1.24) for SBP; 1.20 (1.13 to 1.28) for PP; 1.12 (1.05 to 1.19) for mean arterial pressure; and 1.04 (0.98 to 1.11) for DBP. The areas under the receiver operating characteristic curve were slightly higher for SBP and PP compared with mean arterial pressure and DBP for major cardiovascular and coronary events. Using achieved instead of baseline blood pressure values marginally improved the effect estimates for SBP, DBP, and mean arterial pressure, with no significant differences in the areas under the receiver operating characteristic curve between models with SBP and those with PP. [1] [2] [3] However, there is still a continuing debate on the prognostic significance of different BP indices on cardiovascular events, and uncertainty remains regarding their relative importance in predicting risk. From a historical perspective, the initial focus was on diastolic BP (DBP), primarily driven by experience from early clinical trials. 4 The progressive accumulation of evidence from observational studies 5-7 suggested that systolic BP (SBP) is a better indicator. 4, 8, 9 Subsequently, pulse pressure (PP) was also shown to be an important predictor of the risk of CVD, particularly in middle-aged and older individuals. 8,10 -13 More recently, analyses conducted in a younger population have suggested that a combination of BP indices could be superior to single components for predicting the risk of CVD. 14, 15 Age-related changes in BP indices have been described across populations, with SBP rising continuously throughout life, whereas DBP tends to remain constant, or even decline, after the fifth and sixth decades. 16 As a result, PP also rises continuously, with some acceleration in later life. 16 Data from 2 large meta-analyses of cohort studies have shown a consistent attenuation of the association between BP indices and cardiovascular risk with increasing age. 9,17 They have also
demonstrated that SBP alone was slightly more informative compared with the other BP indices, that PP was less informative than SBP, and that this was particularly true in those aged Ͻ50 years. 9, 17 Insulin resistance and type 2 diabetes mellitus are associated with premature stiffening of small and large arteries. 18, 19 Given that PP is a marker of arterial stiffness and a predictor of CVD and total death, 20 it has been postulated that PP might be a better predictor of CVD in individuals with type 2 diabetes mellitus compared with other BP variables. 21 However, the relative importance of different BP indices in predicting the risk of CVD and death in individuals with type 2 diabetes mellitus has not been clearly established. [21] [22] [23] [24] Importantly, none of these studies has assessed the discriminatory capabilities of BP indices in predicting the risk of CVD in individuals with type 2 diabetes mellitus.
The objective of the present report was to assess and compare the ability of each BP index and their combinations to predict cardiovascular risk among participants in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) Study. [25] [26] [27] [28] 
Methods
The study protocol for ADVANCE and the main results relating to BP and glucose lowering have been detailed elsewhere. [25] [26] [27] [28] In brief, ADVANCE was a 2ϫ2 factorial randomized, controlled trial of BP and glucose lowering on the incidence of microvascular and macrovascular events among individuals with type 2 diabetes mellitus. Participants had to be Ն55 years of age at entry, to be diagnosed with diabetes mellitus at the age of 30 years or older, and to have Ն1 other risk factor for CVD. A total of 11 140 patients recruited from 215 centers across 20 countries were randomly allocated to a fixed combination of perindopril and indapamide (nϭ5569) or matching placebo (nϭ5571) and an intensive gliclazide modified releasebased glucose control regimen or standard blood glucose control. They were followed-up for a mean duration of 4.3 years, at which time the BP intervention was terminated.
Baseline Assessment
The baseline BPs presented here are those obtained at the initial registration visit. Three separate measurements of BP were recorded using an Omron HEM-705CP instrument, after 5 minutes rest, with the participant in a seated position. PP (in millimeters of mercury) was calculated as the difference between systolic and diastolic BPs and mean arterial BP (in millimeters of mercury) as the sum of diastolic BP and one third of PP. In addition, baseline data were collected on medical history, current medical treatment, and major risk factors.
Cardiovascular Outcomes
Outcomes were restricted to the first event recorded during followup. Major CVD was a composite of major coronary and major cerebrovascular events. Major coronary events included death from coronary heart disease, sudden death, and nonfatal myocardial infarction. Major cerebrovascular events included death from cerebrovascular events and nonfatal stroke. Outcomes were coded according to the International Classification of Diseases, 10th Revision, and major events (suspected myocardial infarction, suspected stroke, and all deaths) were centrally validated by an independent end point committee.
Statistical Methods
Cox proportional hazard regression models were used to estimate the hazard ratio (HR) and 95% CI for a 1-SD higher level of each BP variable. HRs (95% CI) for the participants in the upper fifth of BP variables distribution, as compared with those in the lowest fifth, were also computed. Age, sex, and treatment allocation groupadjusted HRs are presented. Additional adjustments for smoking status, total cholesterol HbA1c, and known duration of diabetes mellitus were also made. Similar analyses were also performed using achieved instead of baseline BP. Achieved BP was defined as the mean of all of the available BP measurements before the first event for those who had an event and the mean over the whole randomized phase of the trial for those who did not. Interactions between age, sex, known duration of diabetes mellitus, treatment allocation group, and each BP variable were tested for each outcome, as well as the potential quadratic interaction terms of each BP variable.
The ability of BP variables to discriminate between participants who developed an event during follow-up and those who did not was assessed using area under the receiver operating characteristic curves (AUCs) and the relative integrated discrimination improvement (RIDI), 29, 30 which measures the percentage of increased discrimination when an extra variable is added to a prediction model. AUC comparison used nonparametric methods 31 implemented with the SAS %ROC macro. 32 Bootstrap methods were used to derive the 95% CI for the RIDI estimates, which were based on 1000 replications.
Secondary analyses were conducted testing for the combination of BP variables (SBPϩDBP or PPϩmean arterial pressure [MAP] ). The likelihood-ratio 2 test between models with a single BP index and the equivalent model with 1 additional index were used to assess improvement in model fit. All of the analyses used SAS/STAT software v 9.1 (SAS Institute, Inc).
Results
Baseline characteristics of the study population are given in Table 1 . During follow-up, 1000 major cardiovascular events (8.9%), 559 major coronary events (5.0%), 433 major cerebrovascular events (3.9%), and 468 cardiovascular deaths treatment-adjusted HRs (95% CI) for each SD increase for major cardiovascular events were as follows: 1.17 (1.10 to 1.24) for SBP, 1.20 (1.13 to 1.28) for PP, 1.12 (1.05 to 1.18) for MAP, and 1.04 (0.98 to 1.11) for DBP ( Figure 1 ). For coronary events, cerebrovascular events, and cardiovascular death, a similar pattern, with comparable levels of association, was observed. A significant quadratic interaction was observed for DBP with major CVD, major coronary events, and CVD deaths. The patterns of these associations were broadly consistent after further adjustment. There was no consistent interaction among the 4 BP variables and age, sex, known duration of diabetes mellitus, and treatment allocation for any outcome. The associations were similar when the upper fifth of each BP variable was compared with the lowest fifth ( Figure 1 ). When achieved BP variables were used as predictors, there was a reversal of the marginal advantage of PP observed using baseline variables, so that the effect sizes for achieved SBP and/or MAP were higher than those for PP for all of the outcomes, except for major coronary events (where the effect size was similar for SBP and PP; Figure 2 ). Again, these associations were similar when the upper fifth of each achieved BP variable was compared with the lowest. In contrast to the relationship with baseline BPs, achieved DBP was continuously and significantly related to all of the outcomes down to the level of 50 mm Hg.
For prediction of major cardiovascular events, there was no significant difference in the AUCs between the 4 BP indices (P value for differencesϭ0.055; Table 2 ). In pairwise comparisons, there was no significant difference in models with either SBP or PP as predictors (Pϭ0.209), and these 2 models were better than those with either DBP or MAP (Table 2) . Using achieved BP variables, there was no difference in the 4 AUCs (overall Pϭ0.077) for discriminating major cardiovascular events (Table S1 , available in the online data supplement available at http://hyper.ahajournals.org).
The RIDI statistics are presented in Table 3 . Significant decreases of 13.0% (major cardiovascular), 13.3% (major coronary), 15.3% (major cerebrovascular), and 5.7% (cardiovascular death) of the RIDI were observed when baseline DBP was used instead of baseline SBP in models adjusted for age, sex, and treatment allocation at baseline. These results indicate a worsening in the predictive value of the models using DBP instead of SBP. A similar pattern was observed when using MAP instead of SBP. In contrast, having PP instead of SBP in the model enhanced the predictive value for major cardiovascular events, major coronary events, and cardiovascular deaths, albeit by a small margin. The advantage of using PP or MAP instead of DBP was apparent for all of the outcomes. When using achieved BP variables, models with SBP were always better than models with any of the 3 other variables for predicting major CVD and CVD death. For these same outcomes, models with MAP were also better than models with PP or DBP (Table 3) .
Models combining 2 variables, eg, SBP and DBP or PP and MAP, provided similar improvements in the prediction of CVD. However, these combined models were not superior to PP alone when using baseline BP values or to SBP alone when using achieved BP values (Tables S2 and S3 ).
Discussion
To the best of our knowledge, this study has, for the first time, presented a comprehensive comparison of the 4 BP indices 
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for risk of major CVDs in a large contemporary population of individuals with type 2 diabetes mellitus. Positive and continuous associations were observed between SBP, PP, MAP, and major cardiovascular outcomes. The relative magnitude of the associations appears similar among these 3 BP indices. By comparison, DBP performed less well than the other indices in predicting risk in this population. AUC comparisons indicated that the discrimination capabilities of BP indices were broadly similar, except for DBP. When using the RIDI analyses, PP (for baseline BP variables) and SBP (for achieved BP variables) exhibited marginal advantages as potential predictors. There was no obvious benefit to the use of a combination of indices compared with a single index.
The associations described in this study between each BP variable and major cardiovascular outcomes are in line with findings from most individual cohort studies and meta-analyses of cohort studies. 21, 22, 24, [33] [34] [35] [36] Two previous studies in people with diabetes mellitus have provided comparative data for the 4 BP indices, 22,24 and 2 others have only compared SBP, DBP, and PP but not MAP. 21, 23 Collectively, these studies did not observe a significant difference between BP indices.
There is increasing interest regarding the association between BP variables and CVD risk in the general population, with a particular focus on PP. Some have suggested that PP is the best predictor, 37 whereas others have not. 6 statistical techniques used to analyze the data could help to explain the discrepancies between these studies. For instance, most comparisons have been based on AUCs from competing models. However, limitations of the AUC as a comparative measure of accuracy between models are now well known. 38 This was manifest in the present analyses where the AUC did not differentiate between competing models with each BP index, regardless of the outcomes under consideration. A recently proposed measure, namely, the RIDI percentage statistic, 29, 30 appears to be useful for assessing differences in the performance of predictive models. The impact of different BP indices on cardiovascular morbidity or mortality risk in the general population has been clarified in 2 large meta-analyses of prospective cohort studies across various settings. 9, 17 The principal findings of these data were that there was an attenuation of the association between BP indices and cardiovascular risk with age, that SBP alone was slightly more informative compared with any other BP combination, and that this was particularly true in subjects aged Ͻ50 years. There are few comparable data from populations with type 2 diabetes mellitus, and none has previously compared the predictive value of different BP indices on both cardiovascular morbidity and mortality. As extensively reviewed by Stehouwer et al, 20 arterial stiffening occurs early in the evolution of the diabetic state, and diabetes mellitus acts as an accelerator of the aging process. 22 It is not surprising, therefore, that, in a population aged 66 years old, with a 7-year median duration of diabetes mellitus and with more than a third having a history of CVD at baseline, SBP and PP should emerge as the best predictors.
Perspectives
SBP, PP, and MAP were all independent predictors of major CVD in the ADVANCE Study, whereas DBP was not. The effect sizes for the associations between these 3 variables and the risk of major CVD were similar. Comparisons of the discriminatory capabilities of these indices suggest that SBP and PP are superior to MAP and DBP. In conclusion, this observational analysis from the ADVANCE Study suggests that SBP and PP are the 2 most effective predictors and DBP is the least effective predictor of the risk of CVDs in a diabetic population, aged 66 years old and with a high prevalence of history of CVD at baseline. However, SBP may be the simplest and most useful predictor across a wider range of age groups and populations. 
